



BRAWN



142B8

CIN NO.: L74899DL1985PLC022468

To,
The Secretary,
Listing Department,
BSE Limited,
Floor 25, Phirozee Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400001

Date: 21-08-2020

Sub: Outcome of 2nd/2020-21 Board Meeting and Submission of Un-audited Financial Results for the quarter ended 30.06.2020

SCRIP CODE: 530207

Dear Sir/ Ma'am,

Pursuant to Regulations 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of the Company, at its meeting held today i.e. Friday, August 21, 2020 inter-alia considered and approved/noted the following:

1. Un-audited Standalone Financial Results of the Company for the quarter ended June 30, 2020 along with the Limited Review Report in this regard, a copy of the said Financial Results together with the Limited Review Report is enclosed herewith.
2. The 35th Annual General Meeting of the Shareholders of the company will be held on Friday, the 25th Day of September, 2020 at 11:00 A.M through video conferencing or other audio visual mode.
3. Approved the Board's report of the Company for 35th Annual General Meeting of the Company.
4. Appointed Secretarial Auditor and Internal Auditor of the Company for the Financial Year 2020- 21.

The meeting of the Board of Directors commenced at 1:30 P.M. and concluded at 3:30 P.M. Please acknowledge the receipt of the Letter and take the same on record.

You are requested to take above on record.

Thanking you,

For BRAWN BIOTECH LIMITED

For Brawn Biotech Limited


Priyanka Sharma
Company Secretary & Compliance Officer

Encl: As above

BRAWN BIOTECH LTD.
(Formerly Known as Brawn Pharmaceuticals Ltd.)

...for better life

Regd. Office : 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 0124-4666152, 4222462,
Email: solution@brawnbiotech, Website : www.brawnbiotech.com

Export Office : 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 011-23275208 Fax : 011-23275208

Corporate Office : Plot No. - 30, Sector - 33, Near Hero Honda Factory, Gurugram (Haryana) 122001, Tel: 0124-4666152, 4222462
Email: solution@brawnbiotech.com

Works : 13, Industrial Area, N.I.T., Faridabad - 121001 (Haryana) Tel : +91-8010416849/48



BRAWN


CIN NO.: L74899DL1985PLC022468

| BRAWN BIOTECH LIMITED | | | | |
|--|---|----------------|----------------|-----------------|
| CIN:L74899DL1985PLC022468 | | | | |
| REGD. OFFICE: 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 | | | | |
| STATEMENT OF STANDALONE UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE 2020 | | | | Rs. In Lacs |
| Sr. No. | Particulars | Quarter Ended | | Year Ended |
| | | 30-Jun-20 | 31-Mar-20 | 31-Mar-20 |
| | | Un-audited | Audited | Audited |
| 1 | Revenue from operations | | | |
| | Revenue from operations | 743.23 | 666.65 | 4,961.62 |
| | Other Income | 0.05 | 10.87 | 17.09 |
| | Total Revenue | 743.28 | 677.52 | 4,978.71 |
| 2 | Expenses | | | |
| a | Cost of material consumed | - | - | - |
| b | Purchase of stock-in-trade | 694.25 | 412.41 | 4,215.31 |
| c | Change in inventories of finished goods, work in progress and stock in trade | (3.25) | 20.08 | (5.02) |
| d | Employee Benefit expenses | 40.61 | 84.26 | 308.28 |
| e | Depreciation and amortisation expenses | 0.88 | 0.92 | 3.47 |
| f | Finance Cost | 0.26 | 1.67 | 4.94 |
| g | Other expenses | 31.98 | 196.45 | 369.75 |
| | Total Expenses | 764.73 | 715.79 | 4,896.73 |
| 3 | Profit from Operation before Other Income, exceptional and extra-ordinary items (1-2) | (21.44) | (38.27) | 81.98 |
| 4 | Other Income | - | - | - |
| 5 | Profit from ordinary activities before exceptional items (3-4) | (21.44) | (38.27) | 81.98 |
| 6 | Exceptional Items | - | - | - |
| 7 | Profit from ordinary activities before tax (5-6) | (21.44) | (38.27) | 81.98 |
| 8 | Tax Expenses | - | (6.00) | 22.85 |
| 9 | Profit (Loss) for the period from continuing operations (7-8) | (21.44) | (32.27) | 59.13 |
| 10 | Profit/(Loss) from discontinuing operations | - | - | - |
| 11 | Tax expense of discontinuing operations | - | - | - |
| 12 | Profit/(loss) from Discontinuing operations (after tax) (10-11) | - | - | - |
| 13 | Profit (Loss) for the period (9+12) | (21.44) | (32.27) | 59.13 |
| 14 | Other Comprehensive Income | (6.41) | 8.37 | 1.30 |
| | Total Comprehensive Income | (27.85) | (23.90) | 60.43 |
| 15 | Details of equity share capital | 300.03 | 300.03 | 300.03 |
| | Paid-up equity share capital | | | |
| | Face value of equity share capital | | | |
| 16 | Reserve excluding Revaluation Reserve | | | |
| 17 | Earnings per share | | | |
| i | Basic earnings per share | (0.93) | (0.80) | 2.01 |
| ii | Diluted earnings per share | (0.93) | (0.80) | 2.01 |

NOTES:-

- Results for the quarter ended on 30th June, 2020 were reviewed by the Audit committee and then approved by the Board of Directors at their meeting held on 21st August, 2020.
- W.e. f. 01.04.2020, the company has revised agreement executed with M/s Brawn Laboratories Limited towards profit margin on export of goods procured from Brawn Laboratories Limited as per specification provided by the company.
- The Company has considered the possible effects that may arise out of the still unfolding COVID-19 pandemic on the carrying amounts of property, plant & equipment, intangible assets, inventories, trade receivables, etc. For this purpose, the Company has considered internal and external sources of information up to the date of approval of the Financial Results. Based on the current estimates, the Company does not expect any significant impact on such carrying values. The impact of COVID-19 on the Company's financial statements may differ from that estimated as at the date of approval of Financial Results.
- The Statutory Auditors carried out the limited review for quarter ended 30th June, 2020. The management has exercised necessary due diligence to ensure that the financial results provided a true and fair view of its affairs.
- The above results have been prepared in compliance with the recognition and measurement principles of the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), as amended by the Companies (Indian Accounting Standards) (Amendment) rules, 2016 prescribed under Section 133 of the companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- The Company is engaged primarily in the business of Pharmaceuticals. Accordingly, there is no separate reportable segments as per Ind-AS 108 dealing with Operating Segments.
- The above Standalone Un-audited Financial Results for the quarter ended on 30.06-2020 are available on company's website www.brawnbiotech.com and BSE website www.bseindia.com.
- Previous year / period figures have been regrouped / rearranged, wherever necessary to make them comparable with the current period figures.

For and on behalf of Board
For Brawn Biotech Limited



Brij Raj Gupta
Director
DIN NO. 00974969
Date: 21-08-2020
Place: Delhi

BRAWN BIOTECH LTD.

(Formerly Known as Brawn Pharmaceuticals Ltd.)

... for better life

Regd. Office : 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 0124-4666152, 4222462, Email: solution@brawnbiotech.com, Website : www.brawnbiotech.com

Export Office : 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 011-23275208 Fax : 011-23275208

Corporate Office : Plot No. - 30, Sector - 33, Near Hero Honda Factory, Gurugram (Haryana) 122001, Tel: 0124-4666152, 4222462 Email: solution@brawnbiotech.com

Works : 13, Industrial Area, N.I.T., Faridabad - 121001 (Haryana) Tel.: +91-8010416849/48



RAJIV UDAI & ASSOCIATES
CHARTERED ACCOUNTANTS

To,
The Board of Directors of
Brawn Biotech Limited

We have reviewed the accompanying statement of unaudited financial results of Brawn Biotech Limited for the period ended 30th June 2020. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not modified in respect of this matter.

For Rajiv Udai & Associates
Chartered Accountants
Firm Registration No. 018764N



Rajeev Jain
Partner

Membership No. 099767
UDIN: 20099767AAAAFD5726



Place: Delhi
Date: 21-08-2020